Key Highlights
- Tevogen (NASDAQ:TVGN) reported a third-quarter net loss of USD 7.0 million, compared with USD 5.7 million a year earlier, while the net loss per share attributable to common stockholders was USD 1.76.
- General and administrative expense rose to USD 3.9 million from USD 2.6 million on higher stock-based compensation, while Research and Development expense eased to USD 3.0 million from USD 3.1 million.
- Cash was USD 144,713 at September 30, 2026, against USD 552,372 at December 31, 2025, and the stockholders' Deficit widened to USD 11.3 million.
- After the quarter, the company repaid USD 7.4 million of Loan principal and USD 177,880 of interest by issuing 1,023,733 shares on November 2, 2026.
Stock Compensation Lifts a USD 7.0 Million Quarterly Loss
Tevogen (NASDAQ:TVGN) filed its Quarterly Report on November 16, 2026. The Warren, New Jersey company describes itself as a healthcare Business spanning Tevogen Bio, which develops off-the-shelf T cell immunotherapies using its ExacTcell platform, Tevogen.AI, and a newly formed healthcare services initiative. Total operating expenses for the quarter were USD 6.9 million against USD 5.7 million, and the net loss was USD 7.0 million. Non-cash stock-based compensation within general and administrative expense reached USD 2.4 million, up from USD 1.2 million. For nine months the net loss narrowed to USD 18.2 million from USD 21.6 million, as general and administrative spending fell to USD 8.6 million from USD 12.5 million.
TVGN 489 Program and a Slimmer Research Budget
Research and development expense was USD 3.0 million in the quarter, with other clinical and preclinical costs falling to USD 94,187 from USD 208,152. The lead candidate, TVGN 489, is aimed at COVID-19 in immunocompromised and high-risk elderly patients, and the company reports a completed Phase 1 proof-of-concept trial with no dose-limiting toxicities. Nine-month research spending was USD 9.4 million against USD 9.0 million. Operating Activities used USD 7.7 million over nine months, compared with USD 10.1 million, and financing brought in USD 7.3 million, mostly pre-funded Warrant proceeds of USD 3.0 million, loan draws of USD 3.0 million and USD 1.3 million from share sales.
Loan Amendment Turns USD 7.4 Million of Debt Into Equity
Tevogen (NASDAQ:TVGN) amended its Facility with the Patel Family on October 27, 2026, extending the draw period to May 31, 2029, capping new borrowings at USD 28.6 million and fixing the share price for principal and interest at USD 7.40. It then repaid all USD 7.4 million of principal and USD 177,880 of interest in stock, eliminating liabilities under the facility. Separately, about 322,000 shares were sold under its at-the-market agreement for roughly USD 6.4 million of gross proceeds through November 12, and 374,994 shares were issued when pre-funded warrants were exercised. Total current liabilities were USD 6.4 million and 68,678,743 shares were outstanding on November 16, 2026.
Where Things Stand
The quarter shows a company funded mainly by related-party financing and small share sales, with cash of USD 144,713 and a stockholders' deficit of USD 11.3 million. Tevogen (NASDAQ:TVGN) has converted its loan to equity, which removes that debt but adds to the share count, and it states that further Capital will be needed to carry out its development plans. Next markers include new draws under the amended facility, the committed USD 7.0 million KRHP grant funding, progress on TVGN 489 trials, and any further sales under the at-the-market agreement.


_11_18_2026_14_48_04_195267.jpg)



Please wait processing your request...